Two more Cambridge companies price their shares

The pace of initial public offerings by Massachusetts biotechnology companies continues to pick up momentum, as a pair of Cambridge companies that previously filed to go public priced their shares this week.

Acceleron Pharma Inc., which is developing protein-based drugs to treat rare blood disorders, said Friday it will seek to raise about $65 million by offering 4.7 million shares to public investors at a price range of between $13 and $15 a share.


On Thursday, Bind Therapeutics Inc., which is developing programmable drugs to treat lung cancer and prostate cancer, indicated it plans to raise $71 million by selling 4.7 million shares at a range of $14 to $16.

Once they begin trading, Acceleron would be listed as XLRN and Bind as BIND on the Nasdaq stock exchange.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

The companies would join five other Massachusetts biotechs that have completed IPOs this year: Enanta Pharmaceuticals Inc. and Tetraphase Pharmaceuticals Inc. of Watertown and Cambridge-based Epizyme Inc., Bluebird Bio Inc., and Agio Pharmaceuticals Inc. Another biotechnology company, Foundation Medicine Inc. of Cambridge registered for an IPO at the end of July.

Robert Weisman

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of